{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/304536392"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "The merger, which is expected to close in the 2009 fourth quarter, is subject to the satisfaction of customary closing conditions and regulatory approvals, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrus...Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "bio-medicine.org" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/283906772"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/304536392" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/461690062"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/304536392"] } } }
